EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors

Jay Patel iD, Samarth Shah, Alayka Reddy, Deep Prajapati, Abhijit Pandya, Sumit Sawhney

Journal of Clinical Medicine Research · 2026-03 · 18 (3) · 121-141

DOI: 10.14740/jocmr6523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine Research, 2026-03. Verfasst von Jay Patel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Florida Atlantic University, Boca Raton, FL, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The statins remain the foundation of lipid management because they lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular events, and guidelines recommend stepwise intensification, often with ezetimibe first, when targets are not met or when intolerance limits dosing. This review introduces a mechanism-first, phenotype-guided framework that links add-on therapies to the dominant driver of residual risk, LDL-C, triglyceride-rich lipoproteins, elevated lipoprotein(a), or inherited dyslipidemia while integrating trial evidence with clinical practicality. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies remain the best-validated add-on for very high-risk patients. FOURIER and ODYSSEY OUTCOMES demonstrated event reduction with evolocumab or alirocumab on background statin therapy. For patients who cannot tolerate adequate statin doses, bempedoic acid provides liver-selective inhibition of adenosine triphosphate (ATP)-citrate lyase, and CLEAR Outcomes showed fewer major cardiovascular events in statin-intolerant populations. Inclisiran extends PCSK9 pathway suppression through hepatic small interfering RNA (siRNA) and enables durable LDL-C reduction with twice-yearly maintenance dosing, offering an adherence-oriented alternative while outcomes data mature. Angiopoietin-like protein 3 (ANGPTL3)-directed therapies (evinacumab and investigational RNAi agents such as zodasiran) lower atherogenic lipoproteins through largely LDL receptor independent biology. They expand options for refractory disease, including homozygous familial hypercholesterolemia. Apolipoprotein C-III (ApoC-III) inhibitors (olezarsen and plozasiran) drive large triglyceride reductions that can be decisive in severe hypertriglyceridemia and pancreatitis-prone syndromes. Next-generation cholesteryl ester transfer protein (CETP) inhibition (notably obicetrapib) has re-emerged as an oral strategy with substantial lipid effects as outcomes programs progress. High-dose eicosapentaenoic acid (EPA) (icosapent ethyl) has the clearest triglyceride-focused outcomes signal; REDUCE-IT showed significant ischemic event reduction in statin-treated patients with persistent hypertriglyceridemia. Early in vivo PCSK9 gene-editing is considered a potential one-time approach, though safety and durability concerns remain unresolved. Implementation remains rate-limiting. Costs, prior authorization, variable coverage, distribution, injection logistics, and adherence barriers delay initiation and erode persistence. Uninsured patients may face prohibitive out-of-pocket expenses without assistance pathways.

Schlagwörter

Stichwörter der Autor:innen

CardiovascularCholesterolDyslipidemiaGene-based lipid therapyLipidLipid metabolismLow-density lipoproteinPCSK9 inhibitorStatin

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Florida Atlantic University, Boca Raton, FL, USA.
  • Department of Technology and Clinical Trials, Advanced Research LLC, Pompano Beach, FL, USA.
  • Oncology and Hematology Associates of West Broward, Coral Springs, FL, USA.

ORCID-Profile: Jay Patel

Zitieren

APA

Patel, J., Shah, S., Reddy, A., Prajapati, D., Pandya, A., & Sawhney, S. (2026). Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. Journal of Clinical Medicine Research, 18(3), 121-141. https://doi.org/10.14740/jocmr6523

Vancouver

Patel J, Shah S, Reddy A, Prajapati D, Pandya A, Sawhney S. Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors. Journal of Clinical Medicine Research. 2026;18(3):121-141. doi:10.14740/jocmr6523

BibTeX
@article{Patel2026,
  author = {Patel, Jay and Shah, Samarth and Reddy, Alayka and Prajapati, Deep and Pandya, Abhijit and Sawhney, Sumit},
  title = {Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors},
  journal = {Journal of Clinical Medicine Research},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {121--141},
  doi = {10.14740/jocmr6523}
}
Kostenlos starten →